Targeting MAPK4 emerges as a promising therapy for prostate cancer

COVID-19 vaccine candidate, tested at UAB, will start Phase 1 clinical trial
19 February 2021
New Zealand says COVID vaccinations ‘small step in long journey’
20 February 2021

Targeting MAPK4 emerges as a promising therapy for prostate cancer

The battle against late-stage prostate cancer might have found a potential new strategy to combat this deadly disease. Research led by Baylor College of Medicine reveals in the Journal of Clinical Investigation that the enzyme MAPK4 concertedly activates androgen receptor (AR) and AKT, molecules at the core of two cellular signaling pathways known to promote prostate cancer growth and resistance to standard therapy. Importantly, inhibiting MAPK4 simultaneously inactivated both AR and AKT and stopped cancer growth in animal models. The findings open the possibility that targeting MAPK4 in human prostate cancer might provide a novel therapeutic strategy for this disease that is the second leading cause of cancer death in American men.

Comments are closed.